Breaking News Instant updates and real-time market news.

PFE

Pfizer

$40.78

1.25 (3.16%)

, IQV

Iqvia

$124.89

0.21 (0.17%)

04:55
01/30/19
01/30
04:55
01/30/19
04:55

Drug Information Association to hold a conference

Pharmacovigilance & Risk Management Strategies Conference will be held in Washington, D.C. on January 28-30.

PFE

Pfizer

$40.78

1.25 (3.16%)

IQV

Iqvia

$124.89

0.21 (0.17%)

ONCE

Spark Therapeutics

$42.80

1.49 (3.61%)

ALXN

Alexion

$119.57

0.36 (0.30%)

TKPYY

Use TAK

$0.00

(0.00%)

GILD

Gilead

$69.55

1.6 (2.35%)

AMZN

Amazon.com

$1,593.77

-44.23 (-2.70%)

MSFT

Microsoft

$102.93

-2.16 (-2.06%)

BMY

Bristol-Myers

$48.31

0.01 (0.02%)

ABBV

AbbVie

$77.46

0.34 (0.44%)

LLY

Eli Lilly

$115.71

0.72 (0.63%)

AMGN

Amgen

$192.10

0.11 (0.06%)

SNY

Sanofi

$42.63

0.65 (1.55%)

MRK

Merck

$73.22

0.29 (0.40%)

HALO

Halozyme

$15.95

0.28 (1.79%)

ESALY

Eisai

$0.00

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

  • 30

    Jan

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 04

    Feb

  • 04

    Feb

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

  • 16

    Feb

  • 18

    Feb

  • 20

    Feb

  • 25

    Feb

  • 28

    Feb

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 11

    Mar

  • 18

    Mar

  • 18

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

PFE Pfizer
$40.78

1.25 (3.16%)

01/23/19
UBSW
01/23/19
DOWNGRADE
Target $46
UBSW
Neutral
Pfizer downgraded to Neutral from Buy at UBS
UBS analyst Navin Jacob downgraded Pfizer to Neutral and lowered his price target for the shares to $46 from $48.50 after assuming coverage of the name. The analyst cites valuation for the downgrade to Neutral.
01/28/19
UBSW
01/28/19
NO CHANGE
Target $109
UBSW
Buy
Exact Sciences price target raised to $109 from $100 at UBS
UBS analyst Daniel Brennan raised his price target on Exact Sciences (EXAS) to $109 from $100 following meetings with management. The analyst raised his doctor additions forecast as well as his Street-high revenue forecasts and still sees room for upside. He sees the additions upside coming as the result of a doubling of ad spending, the addition of Pfizer (PFE and its salesforce, and the doubling of its own salesforce. Brennan reiterated his Buy rating on Exact Sciences shares.
01/25/19
COWN
01/25/19
NO CHANGE
Target $100
COWN
Outperform
Exact Sciences meeting affirms enthusiasm, says Cowen
Cowen analyst Doug Schenkel met with Exact Sciences (EXAS) management, which he said affirmed his enthusiasm about the company. The analyst said Pfizer (PFE) played a key role in driving Q4 physician adds. He sees little reason for regressed Street expectations and noted that the company is stepping up its pipeline efforts. Schenkel reiterated his Outperform rating and $100 price target and called Exact Sciences a top pick for 2019.
01/23/19
01/23/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Underperform from Sector Perform at RBC Capital with analyst Joseph Spak saying the company's more "tactful messaging" conveys downward pressure to growth expectations and also sees the "realities" of Tesla becoming a volume player highlighting its "challenges to scale and deliver high volume at high ASPs/margins." 2. Lowe's (LOW) downgraded to Hold from Buy at Loop Capital with analyst Laura Champine saying she thinks she was previously too optimistic on Lowe's likely margin progression. 3. Williams-Sonoma (WSM) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman saying he believes top and bottom-line pressures will intensify in 2019. 4. Merck (MRK) downgraded to Market Perform from Outperform at BMO Capital with analyst Alex Arfaei citing the company's over-dependence on Keytruda, the Street's high expectations, and his views on upcoming competitor trials combining for a more balanced risk-reward on Merck. 5. Pfizer (PFE) and Mylan (MYL) were downgraded to Neutral from Buy at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
IQV Iqvia
$124.89

0.21 (0.17%)

01/18/19
JEFF
01/18/19
UPGRADE
Target $150
JEFF
Buy
Iqvia upgraded to Buy from Hold at Jefferies
Jefferies analyst David Windley upgraded Iqvia to Buy and raised his price target for the shares to $150 from $136.
01/11/19
GSCO
01/11/19
UPGRADE
Target $151
GSCO
Conviction Buy
Iqvia upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Robert Jones added Iqvia Holdings (IQ) to his firm's Americas Conviction List while keeping a Buy rating on the shares. The analyst lowered his price target for the shares to $151 from $152. He sees "several drivers of upside" in 2019 against a "very healthy" industry backdrop. Iqvia's backlog growth along with an industry leading book-to-bill indicate its offering is resonating in the market, Jones tells investors in a research note. He believes the company's upcoming commentary accompanying 2019 guidance could serve as a potential catalyst for the shares. Jones is also positive on shares of Icon (ICLR).
01/18/19
JEFF
01/18/19
UPGRADE
Target $150
JEFF
Buy
Jefferies upgrades Iqvia to Buy after encouraging CRO survey
Jefferies analyst David Windley upgraded Iqvia to Buy from Hold and raised his price target for the shares to $150 from $136. The analyst says the results from his firm's annual contract research organization survey show accelerating research and development spending, continued rise in outsourcing, and a "notable rise" in preference for global CROs over niche, private players. These results bode positively for growth in 2019 and beyond, Windley tells investors in a research note. He cites improving positive CRO feedback both in the survey and channel checks for his upgrade of Iqvia. The company has done a commendable job of upping the sales and operational intensity of its business as well as developing and launching integrated application platforms, says Windley.
01/18/19
01/18/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Edwards Lifesciences (EW) upgraded to Buy from Neutral at BofA/Merrill with analyst Bob Hopkins saying he expects Edwards' multiple to move higher as investors digest upcoming pipeline readouts for Low Risk Aortic and Mitral Repair over the next five months. 2. Iqvia (IQV) upgraded to Buy from Hold at Jefferies with analyst David Windley saying the results from his firm's annual contract research organization survey show accelerating research and development spending, continued rise in outsourcing, and a "notable rise" in preference for global CROs over niche, private players. 3. Arista Networks (ANET) upgraded to Buy from Neutral at Nomura Instinet wih analyst Jeffrey Kvaal saying he views the recent pullback in shares as a buying opportunity and he expects "strong" Q4 results and "robust" growth in 2019. 4. Chevron (CVX) upgraded to Buy from Neutral at UBS with analyst Jon Rigby saying the recent pullback in oil prices has presented a buying opportunity in the shares. 5. Sportsman's Warehouse (SPWH) upgraded to Overweight from Neutral at Piper Jaffray with analyst Peter Keith saying the company is "poised for substantially better fundamentals" while the shares trade at the "lowest valuation within our coverage universe." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ONCE Spark Therapeutics
$42.80

1.49 (3.61%)

11/16/18
FBCO
11/16/18
UPGRADE
Target $44
FBCO
Neutral
Spark Therapeutics upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse analyst Martin Auster upgraded Spark Therapeutics (ONCE) to Neutral from Underperform but lowered his price target to $44 from $48. In a research note to investors, Auster says that with uniQure's (QURE) update validating AMT-061, its second generation hemophilia B gene therapy construct incorporating the Padua variant, and Freeline's initial data disclosed in ASH abstracts, he sees a more competitive landscape in hemophilia B gene therapy, and lowered his market share assumptions for SPK-9001 to reflect this new dynamic.However, Auster says Spark has been under significant pressure since providing an update on its hemophilia A, and believes most of the value for that program has already been discounted in the share price. Though there is limited visibility in the near-term, he sees optionality going forward within the Pompe program and/or a possible reemergence of the hem A platform ~mid-2019 from either an improved profile for SPK-8011 with prophy steroids or encouraging early data from Spark's second compound SPK-8016.
11/16/18
FBCO
11/16/18
UPGRADE
FBCO
Neutral
Spark Therapeutics upgraded to Neutral from Underperform at Credit Suisse
11/16/18
11/16/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst James Faucette saying he thinks consensus estimates now imply a more realistic scenario for QCT margins and that lowered expectations on a resolution with Apple (AAPL) gives room for the stock to react positively should legal proceedings trigger a settlement. 2. Spark Therapeutics (ONCE) upgraded to Neutral from Underperform at Credit Suisse with analyst Martin Auster saying with uniQure's (QURE) update validating AMT-061, its second generation hemophilia B gene therapy construct incorporating the Padua variant, and Freeline's initial data disclosed in ASH abstracts, he sees a more competitive landscape in hemophilia B gene therapy, and lowered his market share assumptions for SPK-9001 to reflect this new dynamic. 3. Armstrong Flooring (AFI) upgraded to Buy from Hold at Gabelli with analsyt Alvaro Lacayo saying the sale of the wood business is a transformative deal and removes two underperforming segments that have been under increased pressure from private label competition. 4. DSW (DSW) upgraded to Neutral from Negative at Susquehanna. 5. PG&E (PCG) and Edison International (EIX) were upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/18
HCWC
11/15/18
NO CHANGE
Target $48
HCWC
Buy
uniQure's AMT-061 'living up to high expectations,' says H.C. Wainwright
uniQure (QURE) has provided investors with "a compelling glimpse at what the future hold for Hemophilia B patients" after issuing an update on its AMT-061 dose confirmation study, according to H.C. Wainwright analyst Debjit Chattopadhyay. The mean Factor IX activity at six weeks was 31%, which is on par with Spark Therapeutics' (ONCE) SPK-9001, said Chattopadhyay. The analyst, who thinks AMT-061 is "living up to high expectations" and views it being positioned as "not only the best-in-class one-and-done solution, but also, the first to market," keeps a Buy rating and $48 price target on uniQure shares.
ALXN Alexion
$119.57

0.36 (0.30%)

01/03/19
PIPR
01/03/19
NO CHANGE
PIPR
Piper sees Alexion, Biogen as potential targets after Celgene buyout
Piper Jaffray analyst Christopher Raymond remains "bullish on biotech" in the wake the announced acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) for $74B in cash and stock, representing a 54% premium from yesterday's close. In a research note titled "Bristol for CELG - In Retrospect, it Makes Perfect Sense," Raymond says the market is likely to ask "who's next?" Among large-caps, Alexion Pharmaceuticals (ALXN) and Biogen (BIIB) would seem to make sense as potential targets, as well as BioMarin (BMRN), Raymond writes. And while any smid cap could likely be seen as a take-out candidate, Aimmune Therapeutics (AIMT), Deciphera Pharmaceuticals (DCPH) and Rigel Pharmaceuticals (RIGL) "in particular could make sense to any strategic buyer," adds the analyst.
01/22/19
FBCO
01/22/19
NO CHANGE
Target $156
FBCO
Outperform
Credit Suisse sees limited fundamental impact to Alexion from EU IP setback
Credit Suisse analyst Martin Auster notes that Alexion indicated that the European Patent Office has revoked the new Soliris formulation patent previously granted, following an opposition from potential competitors. The company expects to receive the written decision over the next few weeks, when it will likely appeal the outcome, a process that could take 3-5 years, Auster notes. The analyst believes investors currently assign limited protective value from this formulation patent, with no change to his thesis from a fundamental perspective. He reiterates an Outperform rating and $156 price target on the shares.
01/22/19
PIPR
01/22/19
NO CHANGE
PIPR
Overweight
Piper says Alexion should be bought on EU patent decision headline weakness
Following news that the European Patent Office revoked Alexion's (ALXN) '834 Soliris formulation patent, Piper Jaffray analyst Christopher Raymond noted that the patent has been the subject of an opposition by Amgen (AMGN) in its effort to introduce a biosimilar version of Soliris in Europe. While the headline is "scary," the impact "could be essentially zero," as the appeals process could take 3-5 years, Soliris has EU Orphan data exclusivity for aHUS through November of 2023, so the earliest a biosimilar could receive approval in this indication is likely 2024, and Amgen still needs to run a trial, Raymond tells investors. Given that he sees "extremely limited impact" on Alexion's EU franchise from this 'decision, Raymond said he would be a buyer on weakness and keeps an Overweight rating on Alexion shares.
01/28/19
PIPR
01/28/19
NO CHANGE
Target $180
PIPR
Overweight
Piper a buyer of Alexion on weakness, says Ultomiris data 'look good'
After Alexion released top-line results for a Phase 3 trial of Ultomiris in complement inhibitor-naive aHUS patients, Piper Jaffray analyst Christopher Raymond said he believes the data "look good," stating that a comparison to Soliris is not "apples-to-apples" since management tells him that patients in the Ultomiris study were sicker than Soliris' Phase 3 patients with less favorable metrics across several measures. No new safety signals were observed and although four patient deaths were reported, none were attributed to Ultomiris, Raymond added. The analyst, who would be a buyer of shares on the weakness, keeps an Overweight rating and $180 price target on Alexion.
TKPYY Use TAK
$0.00

(0.00%)

11/06/18
RHCO
11/06/18
NO CHANGE
Target $190
RHCO
Buy
Shire price target lowered to $190 from $205 at SunTrust
SunTrust analyst John Boris lowered his price target on Shire (SHPG) to $190 to reflect the impact of the USD appreciation against GBP while also lowering his FY18 EPS view to $15.11 from $15.18. The analyst notes that the investment focus for Shire falls on the November 20th vote by E.U. regulators on its merger with Takeda (TKPYY), adding that the company is on track to secure that approval and for shareholders to vote on the deal in January of next year.
12/12/18
RHCO
12/12/18
DOWNGRADE
Target $175
RHCO
Hold
Shire downgraded to Hold at SunTrust on Takeda merger
As reported earlier, SunTrust analyst John Boris downgraded Shire (SHPG) to Hold from Buy and lowered his price target to $175 from $190. The analyst cites the changes in FX rates and Takeda (TKPYY) share price in shifting his price target, but expects the deal to close under the same terms on January 8th with no "meaningful hurdles" left to clear until then.
12/20/18
WBLR
12/20/18
DOWNGRADE
WBLR
Market Perform
Shire downgraded to Market Perform from Outperform at William Blair
William Blair analyst Tim Lugo downgraded Shire (SHPG) to Market Perform to reflect the pending takeover by Takeda Pharmaceutical (TKPYY).
09/07/18
BREN
09/07/18
DOWNGRADE
BREN
Hold
Shire downgraded to Hold from Buy at Berenberg
Berenberg analyst Klara Fernandes downgraded Shire (SHPG) to Hold saying the current valuation offers limited potential upside ahead of the pending takeover by Takeda Pharmaceutical (TKPYY).
GILD Gilead
$69.55

1.6 (2.35%)

01/28/19
SBSH
01/28/19
NO CHANGE
Target $106
SBSH
Buy
Citi opens catalyst watch on Gilead ahead of NASH data
Citi analyst Robyn Karnauskas opened a catalyst watch on Gilead Sciences ahead of its 4 selonsertibi data readout in Q1. The analyst sees potential upside for the shares and notes nonalcoholic steatohepatitis represents $11 of her $106 price target on Gilead. She keeps a Buy rating on the stock.
01/03/19
OPCO
01/03/19
UPGRADE
OPCO
Outperform
Gilead upgraded to Outperform from Perform at Oppenheimer
12/19/18
CANT
12/19/18
NO CHANGE
Target $92
CANT
Overweight
Gilead price target raised to $92 from $88 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Gilead Sciences (GILD) to $92 after her firm increased its peak 2027 filgotinib sales estimate from $2.75B to $4.0B. Gilead books revenues in the U.S. and ~20% of sales are outside the U.S., so filgotinib is a key pipeline product not only for Galapagos NV (GLPG), but also for Gilead, Young tells investors in a research note. She reiterates an Overweight rating on the shares.
01/03/19
01/03/19
UPGRADE
Target $85

Outperform
Gilead upgraded to Outperform at Oppenheimer as strong clinical data approaches
As previously reported, Oppenheimer analyst Hartaj Singh upgraded Gilead to Outperform from Perform, with a $85 price target. The analyst believes that in 2019 the addition of CEO Daniel O'Day, year-on-year sales growth, and important mid/late-stage clinical readouts for budding franchises in inflammation and NASH could start to re-rate a biotech bellwether, a name that is among the cheapest in large-cap biotech. After a 3-year stretch where the company lost almost 1/3 of its top line with slowing HCV sales, Singh thinks Gilead is poised to get its "mojo back," delivering on P&L fundamentals, mid/late-stage pipeline progression and a burgeoning acquisition/licensing heightened by O'Day's previous experience.
AMZN Amazon.com
$1,593.77

-44.23 (-2.70%)

01/28/19
WEDB
01/28/19
NO CHANGE
Target $2100
WEDB
Outperform
Amazon can deliver substantial earnings over long-term, says Wedbush
Wedbush analyst Michael Pachter believes Amazon can deliver substantial earnings over the long-term by growing spending more slowly than revenues. Amazon Web Services, Fulfillment by Amazon, and ads should drive steady margin growth, with Prime driving retail revenue growth, he contends. Ahead of quarterly results, Pacther adds that he expects upside from record Black Friday, Cyber Monday, and holiday performances. The analyst reiterates an Outperform rating and $2,100 price target on the shares.
01/28/19
FBCO
01/28/19
NO CHANGE
Target $2100
FBCO
Outperform
Amazon.com price target lowered to $2,100 from $2,400 at Credit Suisse
Credit Suisse analyst Stephen Ju lowered his price target for Amazon ahead of quarterly results as he decreases his revenue estimates for 3P seller commission rates. The analyst believes Amazon will display throughout 2019 better-than-expected unit and revenue growth offset by a slower pace of profit dollar growth given the incremental expense items. Ju expects investors to receive well what should be a more moderate deceleration path. He reiterates an Outperform rating on the shares.
01/29/19
KEYB
01/29/19
NO CHANGE
KEYB
KeyBanc projects $300B cloud jump within five years
KeyBanc analyst Brent Bracelin says that while cloud controversy has surfaced after weak commentary coming out of Intel (INTC), NVIDIA (NVDA), and Lam Research (LCRX) in the last week, the analyst sees the cloud capacity absorption period likely to be short-lived, similar to 2016 and not reflective of robust end demand for SaaS and IaaS offerings. Bracelin is forecasting a $300B-plus jump in annual cloud revenue over the next five years as the industry blossoms to $429B by 2023 on a 27% CAGR. While positive investor sentiment is partially reflected in SaaS valuations, the multi-year opportunity keeps him at an Overweight bias across his SaaS coverage list. Bracelin expects strong cloud results out of Microsoft (MSFT) and Amazon (AMZN) this week to quiet some of the recent controversy.
01/29/19
LOOP
01/29/19
NO CHANGE
Target $2200
LOOP
Buy
FedEx 'inexpensive' for potential purchase by Amazon.com, says Loop Capital
Loop Capital analyst Anthony Chukumba notes the attempts by Amazon (AMZN) to continue its trans-Pacific shipping operation, having recently expanded home delivery service to additional markets with greater air cargo terminal capacity and airline fleet. While the analyst notes that both FedEx (FDX) and UPS (UPS) have downplayed the risks, he sees Amazon's continued expansion as a "slippery slope" for the established shippers that may lead to price cutting. Chukumba contends that "buying is more attractive than building", noting that Amazon could purchase FedEx, which trades at an inexpensive valuation of 10.6-times forward earnings and 6.5-times enterprise value to expected EBITDA multiples. Chukumba also keeps his Buy rating and $2,200 price target on Amazon.
MSFT Microsoft
$102.93

-2.16 (-2.06%)

01/14/19
DBAB
01/14/19
NO CHANGE
DBAB
Buy
Microsoft security Portfolio 'flying below the radar,' says Deutsche Bank
The prevailing Street narrative about Microsoft's (MSFT) security suite is that it is "good enough" for a segment of the market but not particularly competitive against enterprise pure-plays such as Symantec (SYMC), Proofpoint (PFPT) or Okta (OKTA), Deutsche Bank analyst Karl Keirstead tells investors in a research note titled "Security is a New Growth Engine." However, the analyst says his field checks over the last few quarters have indicated a "clear tone shift" from customers and partners, with more flagging material investments by Microsoft in its security suite and real traction among enterprise customers. He believes Microsoft 's security portfolio is "flying below the radar" of most Street analysts and is central to the company's "emerging" average revenue per user growth story. Keirstead keeps a Buy rating on Microsoft.
01/10/19
MSCO
01/10/19
NO CHANGE
Target $130
MSCO
Overweight
Survey gives Morgan Stanley confidence 'secular can trump cyclical' at Microsoft
Morgan Stanley analyst Keith Weiss said the firm's survey of 100 U.S. and European CIOs points to "strong" 2019 IT budget growth expectations of 4.7% year-over-year, which he notes is relatively in line with the 4.9% budget growth expected for 2018. The slight deceleration comes mostly from weaker European spending plans, as growth expectations among U.S. CIOs actually steps up to 5.5% growth called for in 2019 versus 5.3% for 2018, Weiss added. While investors' concerns about the durability of software growth broadly, and the durability of the more cyclical aspects of the Microsoft portfolio, are rising, the CIO survey gives Weiss confidence that the strong secular demand trends driving Microsoft's top-line should trump potential cyclical headwinds, he tells investors. Weiss keeps an Overweight rating on Microsoft with a $130 price target.
01/28/19
BOFA
01/28/19
NO CHANGE
Target $150
BOFA
Buy
Microsoft price target raised to $150 from $140 at BofA/Merrill
BofA Merrill Lynch analyst Kash Rangan noted that the current macro outlook has some investors wondering how cyclical Microsoft is, but he sees its "Cloud-like growth, legacy-like margins and GAARP-like valuation" making the company unique. After a deeper evaluation of its five key growth segments - Azure/server products, Commercial office, Gaming, LinkedIn and GitHub - Rangan views 10-15% revenue growth CAGR as sustainable for 5-7 years, he tells investors. His proprietary survey suggests that near-term demand remain solid and Rangan believes the consensus view is underestimating a potential upgrade cycle from 2008/2012 server versions to 2016/2019 versions over the next 6-12 months, he added. He raised his price target on Microsoft shares to $150 from $140 and keeps a Buy rating on the stock.
BMY Bristol-Myers
$48.31

0.01 (0.02%)

01/24/19
ADAM
01/24/19
NO CHANGE
Target $161
ADAM
Buy
Bluebird Bio's bb2121 'too valuable' for Bristol-Myers to share, says Canaccord
Assuming that the Bristol-Myers (BMY) and Celgene (CELG) transaction closes, Canaccord analyst John Newman said he expects Bristol-Myers will seek 100% control of bb2121 from Bluebird Bio (BLUE), calling the treatment "too valuable" to share due to the large long-term commercial potential and Bristol's deep expertise in commercialization. Stating that Bristol-Myers could try to acquire 100% control of bb2121 from Bluebird via a buyout, U.S. royalty, or higher EU royalty, Newman added that Bristol and Celgene do not have right of first refusal if an acquirer were to tender an offer, which he calls a "favorable setup" for Bluebird shareholders. The analyst, who estimates a Bluebird buyout to obtain the other half of the company could be valued at $8.8B-$10.5B, keeps a Buy rating and $161 price target on Bluebird Bio shares.
01/23/19
MZHO
01/23/19
NO CHANGE
Target $81
MZHO
Buy
Mizuho sees 'significant upside' in Nektar shares, reiterates $81 price target
While shares of Nektar Therapeutics (NKTR) have performed strongly year-to-date, "significant upside remains," Mizuho analyst Difei Yang tells investors in a research note. A recent Nature article on IL-2 immunotherapy and new players in the field provide support for Nektar's approach to immuno-oncology, says Yang. Further, she believes the company's collaborations with large pharma, including Bristol-Myers Squibb (BMY) and Pfizer, underscore the "strong potential" of NKTR-214. With multiple data readouts expected in 2019, Yang sees "significant value" in Nektar shares. She reiterates a Buy rating on the name with an $81 price target. The stock closed yesterday down 3% to $44.76.
01/15/19
01/15/19
UPGRADE
Target $60

Buy
Societe General applauds Bristol-Myers' 'bold' deal, double upgrades to Buy
As previously reported, Societe Generale analyst Justin Smith double upgraded Bristol-Myers (BMY) to Buy from Sell as he believes investors' concerns about how the acquisition of Celgene (CELG) could weaken its long-term growth profile are adequately discounted at the stock's current levels. He also applauds management for making "such a bold strategic move," contending that improved cash flow and a higher R&D budget for the combined company should help it navigate past medium-term patent expirations while simultaneously growing the dividend. He assigns an 80% probability of the acquisition closing, but "cannot dismiss the risk of counter-bids on either side of this deal," Smith added. He raised his price target on Bristol-Myers shares to $60 from $47.
01/22/19
JEFF
01/22/19
NO CHANGE
Target $95
JEFF
Buy
Jefferies does not see possible Bristol-Myers suitor thwarting Celgene deal
Jefferies analyst Michael Yee says that while shares of Bristol-Myers Squibb (BMY) have rallied over the past two weeks, Celgene (CELG) shares are roughly flat, putting the deal spread back to 18%-20%. Celgene has been flat as investors are unsure what will happen with some near-term event volatility, including the inter partes review decision on patents related to methods of use and dosing for Revlimid and the Bristol shareholder vote in the summer, Yee tells investors in a research note. The analyst, however, sees a suitor emerging for Bristol-Myers as the biggest risk to the Celegene buyout. But he does not see an unsolicited suitor coming in to thwart the $74B deal for Celgene. As such, he believes current share levels provide investors an attractive 18%-20% return over the near- to mid-term. Yee keeps a Buy rating on Celgene with a $95 price target.
ABBV AbbVie
$77.46

0.34 (0.44%)

01/03/19
BOFA
01/03/19
DOWNGRADE
Target $95
BOFA
Neutral
AbbVie downgraded to Neutral from Buy at BofA/Merrill
As noted earlier, BofA/Merrill analyst Jason Gerberry downgraded AbbVie to Neutral from Buy and lowered his price target to $95 from $98 as part of his broader research note on the Phamaceuticals sector partially titled "Preference for value, defensive + pipeline optionality". The analyst sees "limited upside to shares" relative to his price objective and also cites a more "unfavorable macro backdrop for companies with high single product concentration risk". Gerber believes that AbbVie would have to "meaningfully beat consensus forecasts on key new product launches" to reduce investor concerns over the loss of exclusivity for Humira and Imbruvica.
01/23/19
UBSW
01/23/19
INITIATION
Target $91
UBSW
Neutral
AbbVie assumed with a Neutral at UBS
UBS analyst Navin Jacob assumed coverage of AbbVie with an unchanged Neutral rating and lowered his firm's price target for the shares to $91 from $97. While the Humira biosimilar threat has been de-risked, the current valuation offers limited upside, says the analyst.
01/03/19
01/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Hold from Buy at Jefferies and Loop Capital, as well as to Neutral from Outperform at Macquarie. 2. Genesee & Wyoming (GWR) downgraded to Equal Weight from Overweight at Stephens with analyst Justin Long citing his view that a re-expansion in valuation multiples could be more challenging in the near-term given North American volume headwinds in the short line network, unknowns around the PSR impact and more concerning international macro data points. 3. Lumber Liquidators (LL) downgraded to Hold from Buy at Loop Capital with analyst Laura Champine saying she reduced her margin forecast to reflect a promotional environment. 4. American Electric (AEP) downgraded to Neutral from Buy at Mizuho with analyst Paul Fremont citing valuation. 5. AbbVie (ABBV) downgraded to Neutral from Buy at BofA/Merrill with analyst Jason Gerberry saying he sees "limited upside to shares" relative to his price objective and also cites a more "unfavorable macro backdrop for companies with high single product concentration risk." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/25/19
PIPR
01/25/19
NO CHANGE
Target $90
PIPR
Neutral
Piper 'not ready to jump back in just yet' to AbbVie shares
Piper Jaffray analyst Christopher Raymond reiterates a Neutral rating on AbbVie shares with a $90 price target following this mornings "rare" Q4 miss. The analyst says Humira missed his below-consensus estimate, driven primarily by biosimilar pressure in Europe. In a research note titled "Humira's Issues Come Home to Roost; Not Ready to Jump Back in Just Yet," Raymond lowered his Humira estimates for fiscal 2019 and beyond and said he continues to prefer the sidelines with respect to the stock. However, with a dividend yield now above 5% and a "number of key drug launches on tap this year, the analyst thinks AbbVie shares are "starting to look interesting."
LLY Eli Lilly
$115.71

0.72 (0.63%)

01/18/19
JPMS
01/18/19
NO CHANGE
JPMS
Overweight
Eli Lilly trial miss a 'moderate setback,' says JPMorgan
JPMorgan analyst Chris Schott calls Eli Lilly's Phase 3 trial miss of Lartruvo in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma a "moderate" setback.
01/18/19
WBLR
01/18/19
DOWNGRADE
WBLR
Market Perform
Loxo Oncology downgraded to Market Perform from Outperform at William Blair
William Blair analyst Raju Prasad downgraded Loxo Oncology (LOXO) to Market Perform citing the likelihood of the takeover by Eli Lilly (LLY) closing at the agreed upon price.
01/23/19
UBSW
01/23/19
INITIATION
Target $131
UBSW
Buy
Eli Lilly initiated with a Buy at UBS
UBS analyst Navin Jacob started Eli Lilly with a Buy rating and $131 price target. The analyst's analysis suggests the company's diabetes franchise growth, Verzenio adjuvant trial success and operating margin expansion are not fully appreciated in the stock or estimates
01/25/19
PIPR
01/25/19
NO CHANGE
PIPR
Report that CVS excluded Amgen's Aimovig 'greatly exaggerated,' says Piper
Piper Jaffray analyst Christopher Raymond kept an Overweight rating and $220 price target on Amgen (AMGN) following a Reuters report from earlier on Friday which stated that CVS (CVS) has excluded Amgen's Aimovig from its formulary. The analyst called the report "Friday afternoon clickbait" and noted that while CVS currently provides preferred status to Teva's (TEVA) Ajovy and Eli Lilly's (LLY) Emgality, this was made public in late 2018. In a check with management, Raymond found out the decision only encompasses about one-third of CVS network, that CVS is actively working to improve this access, and that 70% of commercial migraine patients have contracted access to Aimovig. Raymond concluded that this was "not something to worry about" in his view, and did not change his Q4, FY19, or FY20 estimates on Aimovig. In Friday trading, shares of Amgen were down just over 1% to $198.77.
AMGN Amgen
$192.10

0.11 (0.06%)

01/28/19
01/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Autohome (ATHM) downgraded to Underweight from Neutral at JPMorgan with analyst Binbin Ding saying he expects the company to see weakened pricing power amid a "challenging" market environment. 2. Vale (VALE) downgraded to Hold from Buy at HSBC and Jefferies, to Neutral from Outperform at Macquarie, and to Market Perform from Outperform at BMO Capital. 3. Amgen (AMGN) downgraded to In Line from Outperform at Evercore ISI with analyst Umer Raffat citing increased biosimilar competition and an imminent court decision on Enbrel patents with Sandoz. 4. Dynagas LNG (DLNG) downgraded to Neutral from Buy at B. Riley FBR with analyst Liam Burke saying the company "significantly" reduced its cash distribution in order to strengthen its balance sheet. 5. SunTrust (STI) and U.S. Bancorp (USB) were downgraded to Neutral from Outperform at Baird. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/28/19
PIPR
01/28/19
NO CHANGE
Target $220
PIPR
Overweight
Piper boosts sales estimate for Amgen's Aimovig after physician survey
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Amgen and raised his Q4 Aimovig revenue estimate following recent neurologist survey feedback. In its second full quarter of launch, facing new market entrants Ajovy and Emgality, Aimovig "is in good shape," Raymond tells investors in a research note. Despite new competition, physician-reported share dynamics indicate "strong trends" for Aimovig for Q4 and over the next six months, adds the analyst. He raised his Q4 Aimovig revenue estimate to $50M from $41M, ahead of consensus at $47M, and keeps an Overweight rating on Amgen with a $220 price target.
01/28/19
EVER
01/28/19
DOWNGRADE
EVER
In Line
Amgen downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst Umer Raffat downgraded Amgen to In Line citing increased biosimilar competition and an imminent court decision on Enbrel patents with Sandoz. Raffat sees a reasonable chance the Enbreal patents are not upheld and thinks consensus is not forecasting in a biosimilar Enbrel till mid-2020s. Sandoz has expressed a desire to launch in the wake of a district court decision, and the appeals process will be wrapped up by January 2020 regardless, the analyst wrote in a note to investors. Further, Raffat thinks double patenting is a real concern for Amgen's 2028 patents.
01/29/19
PIPR
01/29/19
NO CHANGE
Target $210
PIPR
Overweight
Amgen price target lowered to $210 from $220 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond lowered his price target on Amgen to $210 after its disappointing FY19 earnings guidance and the higher than anticipated operating expenses for Q4. The analyst also keeps his Overweight rating, noting that its management has a "track record for conservativism with respect to initial guidance" and also citing its impressive launch of Aimovig along with the strong performance by Sensipar and Neulasta.
SNY Sanofi
$42.63

0.65 (1.55%)

01/03/19
MSCO
01/03/19
NO CHANGE
Target $70
MSCO
Overweight
MyoKardia shares oversold on Sanofi collaboration end, says Morgan Stanley
Morgan Stanley analyst Jeffrey Hung said MyoKardia (MYOK) management emphasized that Sanofi (SNY) wanted greater economics and maintained that efficacy and safety did not factor into Sanofi's decision to end their collaboration. His base case assumption is that MyoKardia will find another partner after more mature data are reported and he thinks the shares have been oversold following yesterday's announcement, Hung tells investors. He trimmed his price target on the stock to $70 from $72, but keeps an Overweight rating, stating that he believes the Phase 2 mavacamten data were promising and sees multiple catalysts over the next year.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
01/22/19
SBSH
01/22/19
NO CHANGE
Target $14
SBSH
Buy
Lexicon price target lowered to $14 from $26 at Citi
Citi analyst Yigal Nochomovitz lowered his price Lexicon Pharmaceuticals (LXRX) to $14 following last week's FDA panel on sotagliflozin. The analyst now believes Sanofi (SNY) and Lexicon will likely need to conduct a pilot study on a Risk Evaluation and Mitigation Strategies program for mitigating diabetic ketoacidosis risk before the FDA will consider approving the drug. He keeps a Buy rating on Lexicon.
01/03/19
SBSH
01/03/19
NO CHANGE
Target $70
SBSH
Buy
Citi calls MyoKardia 'more interesting long term play' after Sanofi news
Citi analyst Mohit Bansal says that while some might see Sanofi (SNY) giving back all rights back to MyoKardia (MYOK) as a negative, he sees "significant strategic implications in longer term." The move gives MyoKardia more freedom to employ its "Divide and Conquer" precision strategy, Bansal tells investors in a research note titled "Full control makes MYOK an interesting long term play." The analyst also points out that Sanofi's decision was related to wanting U.S. control over Mavacamten, and is not related to the profile of the products. Bansal lowered his price target for MyoKardia to $70 from $90 and keeps a Buy rating on the shares.
MRK Merck
$73.22

0.29 (0.40%)

01/23/19
01/23/19
DOWNGRADE
Target $80

Market Perform
Merck downgraded to Market Perform from Outperform at BMO Capital
As previously reported, BMO Capital analyst Alex Arfaei downgraded Merck to Market Perform and also lowered his Q4 earnings view to 98c from $1.12 while keeping his $80 price target on the shares. The analyst cites the company's over-dependence on Keytruda, the Street's high expectations, and his views on upcoming competitor trials combining for a more balanced risk-reward on Merck. Arfaei anticipates that Merck's revenue growth would slow after 2021 given the loss of exclusivity for Januvia, adding that the company's pipeline does not look "good enough to offset meaningful Keytruda disruptions."
01/23/19
BMOC
01/23/19
DOWNGRADE
BMOC
Market Perform
Merck downgraded to Market Perform from Outperform at BMO Capital
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
HALO Halozyme
$15.95

0.28 (1.79%)

01/11/19
WELS
01/11/19
NO CHANGE
WELS
Outperform
Halozyme undervalued relative to 'de -risked' assets, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week's update and 2019 outlook. The analyst continues to view the company as undervalued relative to its "highly de -risked" lead Enhanze assets. He sees "significant option value" to the broader Enhanze opportunity and PEGPH20 data.
11/27/18
JMPS
11/27/18
NO CHANGE
Target $21
JMPS
Outperform
Halozyme Phase 3 trial amendment makes sense, says JMP Securities
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.
11/27/18
JEFF
11/27/18
NO CHANGE
Target $9
JEFF
Underperform
Jefferies still sees low likelihood of success for Halozyme's PEGPH20
Following the announced change in the Phase 3 endpoint, Jefferies analyst Eun Yang continues to view probability for success of Halozyme Therapeutics's PEGPH20 in pancreatic cancer as low. The change in the HALO-301 endpoint/data analysis "dampens our confidence further," Yang tells investors in a research note. HALO-301 is a phase 3 global, randomized, double-blind placebo controlled clinical trial evaluating investigational new drug PEGPH20 as a first-line therapy for potential treatment of patients with metastatic pancreas cancer. The analyst remains cautious on Halozyme shares with an Underpeform rating and $9 price target.
11/27/18
CANT
11/27/18
NO CHANGE
Target $27
CANT
Overweight
Halozyme modified Phase 3 design 'a good thing,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating and $27 price target on Halozyme Therapeutics after the company announced that it has made a request to the FDA to change the dual primary endpoints of progression free survival and overall survival of the HALO-301 study to the single primary endpoint of overall survival. On the surface, this "change" can quickly lead to a negative perception of trial progress, Duncan tells investors in a research note titled "Don't Miss the Forest for the Trees - Modified P3 is a Good Thing." However, when assessing the design and rationale, in conjunction with the study remaining blinded, the analyst views the move as "prudent, with the clinical risk thus having been reduced, at least, incrementally." He believes investors appreciate the high-risk in pancreatic cancer, and therefore see low expectations for Phase 3 success being priced into the current share price. Duncan says he has "enhanced non-zero conviction" in the potential for HALO-301 to read out positively in the second half of 2019.
ESALY Eisai
$0.00

(0.00%)

07/10/18
MZHO
07/10/18
NO CHANGE
MZHO
Buy
Biogen, Eisai not sharing details on BAN2401 presentation at AAIC, says Mizuho
After Biogen (BIIB) and partner Eisai's (ESALY) recent announcement that BAN2401 demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulation in a trial of Alzheimer's patients, Mizuho analyst Salim Syed said he has checked with both companies and neither is divulging any details about what sort of data on the trial will be shared at the upcoming AAIC meeting. He maintains a Buy rating and $423 price target on Biogen shares.
08/28/18
PIPR
08/28/18
NO CHANGE
PIPR
Overweight
Piper says Biogen PRIME data has little to change minds of bulls or bears
After Biogen (BIIB) and Eisai (ESALY) announced another year's worth of long term extension data from their ongoing PRIME Phase 1b study of aducanumab, Piper Jaffray analyst Christopher Raymond said he sees little in the release to change the minds of either A-beta bulls or A-beta bears. Raymond, who continues to look toward a full Phase 3 data read-out in early 2020 as the key event for aducanumab, keeps an Overweight rating on Biogen shares.
07/06/18
MSCO
07/06/18
NO CHANGE
Target $369
MSCO
Overweight
Biogen likely to be up 5%-10% on positive Alzheimer's data, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said the fact that Eisai (ESALY) and Biogen's (BIIB) BAN2401 trial achieved positive topline results at an 18 month landmark analysis is a "clear positive" for the perception of aducanumab and he expects Biogen's shares to be up 5% to over 10% following the news. Harrison added that he would expect full data to be reported at the CTAD meeting in October as he thinks the AAIC meeting coming up in late July is too close. He keeps an Overweight rating and $369 price target on Biogen shares.
07/06/18
NOMU
07/06/18
UPGRADE
NOMU
Buy
Eisai upgraded to Buy from Neutral at Nomura Instinet
RHHBY Roche
$0.00

(0.00%)

01/02/19
JPMS
01/02/19
NO CHANGE
JPMS
JPMorgan adds Novo Nordisk to Analyst Focus List, removes Roche
JPMorgan analyst Richard Vosser added Novo Nordisk (NVO) to his firm's European Analyst Focus List while removing Roche (RHHBY).
01/28/19
01/28/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Suncor (SU) initiated with a Neutral at Credit Suisse. 2. Roche (RHHBY) initiated with a Buy at Argus. 3. Dell Technologies (DELL) initiated with an Outperform at RBC Capital. 4. Pareteum (TEUM) initiated with a Buy at Craig-Hallum. 5. PolarityTE (PTE) initiated with a Sell at National Securities while being initiated with an Outperform at Northland. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/28/19
ARGS
01/28/19
INITIATION
Target $40
ARGS
Buy
Roche initiated with a Buy at Argus
Argus analyst John Staszak initiated Roche with a Buy rating and a price target of $40, saying that while some of the company's strong "blockbuster" products are maturing or facing competition from biosimilars, the pipeline of its new programs should support revenues. The analyst is also positive on the company's focus of tailoring treatments to patients by combining its expertise in pharmaceuticals and diagnostics. Staszak expects the sales momentum of Roche to generate "above-industry-average EPS growth over the next two years," adding that his implied price target assumes higher valuation multiples and improved earnings.
01/28/19
FBCO
01/28/19
UPGRADE
FBCO
Neutral
Roche upgraded to Neutral from Underperform at Credit Suisse

TODAY'S FREE FLY STORIES

BA

Boeing

$344.09

-25.04 (-6.78%)

08:31
10/19/19
10/19
08:31
10/19/19
08:31
Periodicals
Boeing recovery getting 'a lot more complicated,' Barron's says »

Boeing shares fell on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GMVHF

GVC Holdings

$0.00

(0.00%)

08:27
10/19/19
10/19
08:27
10/19/19
08:27
Periodicals
GVC Holdings looking like 'a good bet,' Barron's says »

GVC Holdings' stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYE

National Vision

$22.98

-0.94 (-3.93%)

08:19
10/19/19
10/19
08:19
10/19/19
08:19
Periodicals
Street sees National Vision as a buy, some shorts disagree, Barron's says »

National Vision has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$167.11

2.3 (1.40%)

, HUM

Humana

$289.59

4 (1.40%)

08:13
10/19/19
10/19
08:13
10/19/19
08:13
Periodicals
Healthcare stocks getting 'back on their feet,' Barron's says »

The sector is the second…

CI

Cigna

$167.11

2.3 (1.40%)

HUM

Humana

$289.59

4 (1.40%)

UNH

UnitedHealth

$245.59

1.84 (0.75%)

WCG

WellCare

$274.54

0.09 (0.03%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$123.03

1.47 (1.21%)

TEVA

Teva

$7.50

-0.26 (-3.35%)

AZN

AstraZeneca

$43.86

-0.25 (-0.57%)

BMY

Bristol-Myers

$53.02

0.6 (1.14%)

LLY

Eli Lilly

$108.68

0.24 (0.22%)

GSK

GlaxoSmithKline

$42.52

0.04 (0.09%)

JNJ

Johnson & Johnson

$127.73

-8.47 (-6.22%)

MRK

Merck

$84.68

0.88 (1.05%)

NVS

Novartis

$86.86

-0.395 (-0.45%)

PFE

Pfizer

$36.46

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$46.13

-0.43 (-0.92%)

ANTM

Anthem

$249.55

0.3 (0.12%)

CVS

CVS Health

$66.17

-0.31 (-0.47%)

CNC

Centene

$46.92

-0.28 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 14

    Nov

  • 18

    Nov

  • 07

    Dec

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

COP

ConocoPhillips

$53.99

-0.55 (-1.01%)

08:03
10/19/19
10/19
08:03
10/19/19
08:03
Periodicals
ConocoPhillips stock looking cheap following selloff, Barron's says »

At a time when Wall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 19

    Nov

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

, NFLX

Netflix

$275.40

-17.88 (-6.10%)

08:00
10/19/19
10/19
08:00
10/19/19
08:00
Periodicals
Comcast stacking up better than investors might expect, Barron's says »

If cord-cutting…

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

NFLX

Netflix

$275.40

-17.88 (-6.10%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$45.58

-0.36 (-0.78%)

T

AT&T

$38.46

0.64 (1.69%)

DIS

Disney

$130.91

-1.46 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 07

    Nov

  • 18

    Nov

  • 19

    Nov

  • 21

    Nov

AKS

AK Steel

$2.45

0.055 (2.30%)

, MT

ArcelorMittal

$14.58

0.03 (0.21%)

07:41
10/19/19
10/19
07:41
10/19/19
07:41
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

AKS

AK Steel

$2.45

0.055 (2.30%)

MT

ArcelorMittal

$14.58

0.03 (0.21%)

NUE

Nucor

$51.69

-0.11 (-0.21%)

STLD

Steel Dynamics

$28.71

-0.04 (-0.14%)

TMST

TimkenSteel

$5.42

-0.015 (-0.28%)

X

U.S. Steel

$10.72

0.1 (0.94%)

GM

General Motors

$36.19

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 31

    Oct

  • 01

    Nov

AAVMY

ABN Amro

$0.00

(0.00%)

, BBVA

Banco Bilbao

$5.38

0.07 (1.32%)

04:55
10/19/19
10/19
04:55
10/19/19
04:55
Conference/Events
Institute of International Finance to hold annual meeting »

2019 IIF Annual Meeting…

AAVMY

ABN Amro

$0.00

(0.00%)

BBVA

Banco Bilbao

$5.38

0.07 (1.32%)

BCS

Barclays

$8.48

0.11 (1.31%)

BLK

BlackRock

$445.26

-5.56 (-1.23%)

BNPQY

BNP Paribas

$0.00

(0.00%)

C

Citi

$69.76

0.16 (0.23%)

CAIXY

CaixaBank

$0.00

(0.00%)

CIB

Bancolombia

$49.65

0.12 (0.24%)

CS

Credit Suisse

$12.34

0.045 (0.37%)

EV

Eaton Vance

$44.07

-0.49 (-1.10%)

GS

Goldman Sachs

$206.61

0.13 (0.06%)

HSBC

HSBC

$38.72

-0.165 (-0.42%)

JPM

JPMorgan

$120.60

0.21 (0.17%)

MA

MasterCard

$270.90

-5.74 (-2.07%)

MCO

Moody's

$217.41

-1.33 (-0.61%)

MS

Morgan Stanley

$43.70

0.25 (0.58%)

NYT

New York Times

$29.76

0.21 (0.71%)

PYPL

PayPal

$101.25

-2.38 (-2.30%)

RBS

RBS

$6.14

0.205 (3.46%)

RY

Royal Bank of Canada

$81.49

0.38 (0.47%)

SMFG

Sumitomo Mitsui

$6.87

-0.04 (-0.58%)

SPGI

S&P Global

$250.62

-2.15 (-0.85%)

STT

State Street

$63.40

3.69 (6.18%)

UBS

UBS

$11.35

0.09 (0.80%)

V

Visa

$175.83

-2.11 (-1.19%)

ZURVY

Zurich Insurance

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 04

    Nov

  • 06

    Nov

  • 10

    Nov

  • 12

    Nov

  • 21

    Nov

  • 04

    Dec

  • 10

    Dec

  • 07

    Jan

  • 14

    Jan

  • 14

    Jan

STT

State Street

$63.40

3.69 (6.18%)

20:09
10/18/19
10/18
20:09
10/18/19
20:09
Upgrade
State Street rating change at Keefe Bruyette »

State Street upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SUN

Sunoco

$32.43

0.32 (1.00%)

19:53
10/18/19
10/18
19:53
10/18/19
19:53
Upgrade
Sunoco rating change at BMO Capital »

Sunoco upgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLF

Tandy Leather

$4.61

(0.00%)

18:24
10/18/19
10/18
18:24
10/18/19
18:24
Hot Stocks
Tandy Leather CFO Castillo to step down »

Tandy Leather Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLF

Tandy Leather

$4.61

(0.00%)

18:23
10/18/19
10/18
18:23
10/18/19
18:23
Hot Stocks
Tandy Leather says most recent annual report statements not reliable »

Tandy Leather Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$236.29

0.99 (0.42%)

18:03
10/18/19
10/18
18:03
10/18/19
18:03
Hot Stocks
U.S. lawmakers request Apple restore HKMapp app in Hong Kong »

U.S. Senators Ron Wyden,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

JPM

JPMorgan

$120.60

0.21 (0.17%)

, FB

Facebook

$185.96

-4.435 (-2.33%)

17:59
10/18/19
10/18
17:59
10/18/19
17:59
Periodicals
JPMorgan CEO says Libra 'a neat idea that will never happen,' Reuters says »

JPMorgan (JPM) CEO Jamie…

JPM

JPMorgan

$120.60

0.21 (0.17%)

FB

Facebook

$185.96

-4.435 (-2.33%)

PYPL

PayPal

$101.25

-2.38 (-2.30%)

MA

MasterCard

$270.90

-5.74 (-2.07%)

V

Visa

$175.83

-2.11 (-1.19%)

EBAY

eBay

$38.82

-0.31 (-0.79%)

BKNG

Booking Holdings

$2,012.20

-16.43 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 04

    Nov

  • 21

    Nov

  • 14

    Jan

GLD

SPDR Gold Shares

$140.47

-0.13 (-0.09%)

17:52
10/18/19
10/18
17:52
10/18/19
17:52
Hot Stocks
SPDR Gold Shares holdings rise to 924.64MT from 918.19MT »

This is the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$16.48

0.11 (0.67%)

17:43
10/18/19
10/18
17:43
10/18/19
17:43
Hot Stocks
Teck Resources gets approval for stock buyback for up to 40M class B shares »

Teck Resources has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

OSK

Oshkosh

$77.22

0.46 (0.60%)

17:41
10/18/19
10/18
17:41
10/18/19
17:41
Hot Stocks
Oshkosh awarded $159.14M Army contract for medium tactical vehicle production »

Oshkosh was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 19

    Nov

  • 20

    Nov

OVLY

Oak Valley Bancorp

$16.40

-0.16 (-0.97%)

17:35
10/18/19
10/18
17:35
10/18/19
17:35
Earnings
Oak Valley Bancorp reports Q3 EPS 40c vs. 37c last year »

Reports Q3 NII $10.4M vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNW

FTE Networks

$0.79

-0.0185 (-2.29%)

17:21
10/18/19
10/18
17:21
10/18/19
17:21
Hot Stocks
FTE Networks receives noncompliance notice from NYSE American »

FTE Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$0.45

0.0048 (1.07%)

17:12
10/18/19
10/18
17:12
10/18/19
17:12
Syndicate
Breaking Syndicate news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLMD

Relmada Therapeutics

$20.18

1.07 (5.60%)

17:10
10/18/19
10/18
17:10
10/18/19
17:10
Syndicate
Breaking Syndicate news story on Relmada Therapeutics »

Relmada Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:55
10/18/19
10/18
16:55
10/18/19
16:55
General news
Breaking General news story  »

Dallas Federal Reserve…

NWSA

News Corp.

$13.48

-0.19 (-1.39%)

, NWS

News Corp

$13.79

-0.11 (-0.79%)

16:51
10/18/19
10/18
16:51
10/18/19
16:51
Periodicals
Facebook reaches pact with News Corp., others for news section, WSJ says »

News Corp. (NWSA) has…

NWSA

News Corp.

$13.48

-0.19 (-1.39%)

NWS

News Corp

$13.79

-0.11 (-0.79%)

FB

Facebook

$185.96

-4.435 (-2.33%)

NYT

New York Times

$29.76

0.21 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

  • 06

    Nov

WAIR

Wesco Aircraft

$11.01

0.01 (0.09%)

16:46
10/18/19
10/18
16:46
10/18/19
16:46
Conference/Events
Wesco Aircraft to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:41
10/18/19
10/18
16:41
10/18/19
16:41
Hot Stocks
Breaking Hot Stocks news story on Foamix »

Foamix up 7.5% at $3.35…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.